Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : A US National Health Care System? -- Ignore unavailable to you. Want to Upgrade?

To: skinowski who wrote (7242)	6/29/2009 6:14:20 PM
From: Lane3	Read Replies (1) \| Respond to of 42652

Note that they excluded people with high cholesterol. And yet, they had to stop the study early - because of the difference in outcomes. I'm familiar with that study. Indeed,they excluded people with high cholesterol, which effectively made it a study of the effects of elevated CRP, not about cholesterol at all. Apparently Crestor is effective against CRP. That's good to know. Another tool in the toolkit is always welcome. The question remains, though, whether Crestor would be the first tool out of the toolkit against elevated CRP given that there are other safer and cheaper avenues. I think that a common reading of that study, that we should put Crestor in the water, is not called for. Sure, it's nice that Crestor gives you a twofer, that is it addresses cholesterol and inflammation. I'm sure the Crestor folks are joyous. But the study doesn't do anything to demonstrate that cholesterol should be treated with statins for primary prevention given that the study was about CRP. "The relative risk reductions achieved with the use of statin therapy in JUPITER were clearly significant." Indeed they were. It seems to me that the message from that study is we should give a higher priority to monitoring and reducing CRP as part of primary prevention. LDL, perhaps, has gotten more attention than is warranted. For the time being, imo, a person with several risk factors should be considered for statin therapy. That's the spin, the reaction they want people to have. It's easy to buy, particularly if you're already predisposed to prescribe a statin. I think that reaction is not supported by the evidence. I would amend that to "should be monitored and treated for CRP. If doing so requires a statin, all well and good."